Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Axial Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Jeffrey Young played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Axial Therapeutics

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases. Axial is taking a revolutionary approach to treating neurological diseases. Based on the groundbreaking work from Dr. Sarkis Mazmanian’s lab at Caltech that demonstrated a biological link between Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD) via the gut-brain axis. The idea of a gut-brain axis stems from (i) previous evidence that patients with neurological disorders experience gastrointestinal problems earlier in their disease and/or at the time of diagnosis and (ii) 70% of neurons in the peripheral nervous system, meaning those not in the brain or spinal cord, reside in the intestines and connect to the central nervous system via the vagus nerve.

To learn more about Axial Therapeutics, visit http://axialtx.com/

Contact:
Jeffrey Young, Chief Financial Officer
781-701-8484
jeffrey@axialtx.com
https://www.linkedin.com/in/jeffrey-young-39489718/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved